Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.
Brief Summary: Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment with biological vs no biological agents on vascular and LV function in psoriasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti IL-12 monoclonal antibody/ABT-874; Assigned to Arm(s): 1, 2, 3, 4, 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
C: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2

Answer: C